- Home
- BCIC vs GNLX Comparison
BCIC vs GNLX Comparison
Compare BCIC & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCIC
- GNLX
- Stock Information
- Founded
- BCIC 2006
- GNLX 2001
- Country
- BCIC United States
- GNLX United States
- Employees
- BCIC N/A
- GNLX N/A
- Industry
- BCIC Finance: Consumer Services
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- BCIC Finance
- GNLX Health Care
- Exchange
- BCIC Nasdaq
- GNLX Nasdaq
- Market Cap
- BCIC 159.5M
- GNLX 128.0M
- IPO Year
- BCIC N/A
- GNLX 2023
- Fundamental
- Price
- BCIC $11.69
- GNLX $4.48
- Analyst Decision
- BCIC
- GNLX Strong Buy
- Analyst Count
- BCIC 0
- GNLX 4
- Target Price
- BCIC N/A
- GNLX $17.75
- AVG Volume (30 Days)
- BCIC 62.0K
- GNLX 146.1K
- Earning Date
- BCIC 11-06-2025
- GNLX 11-13-2025
- Dividend Yield
- BCIC 15.92%
- GNLX N/A
- EPS Growth
- BCIC N/A
- GNLX N/A
- EPS
- BCIC N/A
- GNLX N/A
- Revenue
- BCIC $54,317,000.00
- GNLX N/A
- Revenue This Year
- BCIC N/A
- GNLX N/A
- Revenue Next Year
- BCIC $14.84
- GNLX N/A
- P/E Ratio
- BCIC N/A
- GNLX N/A
- Revenue Growth
- BCIC N/A
- GNLX N/A
- 52 Week Low
- BCIC $11.48
- GNLX $1.99
- 52 Week High
- BCIC $18.92
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- BCIC N/A
- GNLX 67.33
- Support Level
- BCIC N/A
- GNLX $4.17
- Resistance Level
- BCIC N/A
- GNLX $4.45
- Average True Range (ATR)
- BCIC 0.00
- GNLX 0.28
- MACD
- BCIC 0.00
- GNLX 0.02
- Stochastic Oscillator
- BCIC 0.00
- GNLX 76.59
About BCIC BCP Investment Corporation Common Stock
BCP Investment Corp is a closed-end, externally managed, non-diversified management investment company. The company invests in performing, well- established middle market businesses that operate across a wide range of industries. It employs fundamental credit analysis, targeting investments in businesses with relatively low levels of cyclicality and operating risk.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.